
1. j med chem. 2014 mar 13;57(5):1976-94. doi: 10.1021/jm301796k. epub 2013 apr 10.

hcv ns5a replication complex inhibitors. part 4. optimization genotype 1a
replicon inhibitory activity.

st laurent dr(1), serrano-wu mh, belema m, ding m, fang h, gao m, goodrich jt,
krause rg, lemm ja, liu m, lopez od, nguyen vn, nower pt, o'boyle dr 2nd, pearce 
bc, romine jl, valera l, sun jh, wang yk, yang f, yang x, meanwell na, snyder lb.

author information: 
(1)departments †medicinal chemistry, ‡virology, §computer-aided drug
design, bristol-myers squibb research development , 5 research parkway,
wallingford, connecticut 06492, united states.

a series symmetrical e-stilbene prolinamides originated the
library-synthesized lead 3 studied respect hcv genotype 1a (g-1a) and
genotype 1b (g-1b) replicon inhibition selectivity bvdv and
cytotoxicity. sar emerging examination prolinamide cap region
revealed 11 selective hcv ns5a inhibitor exhibiting submicromolar potency
against g-1a g-1b replicons. additional structural refinements resulted 
in identification 30 potent, dual g-1a/1b hcv ns5a inhibitor.

doi: 10.1021/jm301796k 
pmid: 23573957  [indexed medline]

